Literature DB >> 23197431

Systemic barriers accessing HIV treatment among people who inject drugs in Russia: a qualitative study.

Anya Sarang1, Tim Rhodes, Nicolas Sheon.   

Abstract

Achieving 'universal access' to antiretroviral HIV treatment (ART) in lower income and transitional settings is a global target. Yet, access to ART is shaped by local social condition and is by no means universal. Qualitative studies are ideally suited to describing how access to ART is socially situated. We explored systemic barriers to accessing ART among people who inject drugs (PWID) in a Russian city (Ekaterinburg) with a large burden of HIV treatment demand. We undertook 42 in-depth qualitative interviews with people living with HIV with current or recent experience of injecting drug use. Accounts were analysed thematically, and supplemented here with an illustrative case study. Three core themes were identified: 'labyrinthine bureaucracy' governing access to ART; a 'system Catch 22' created by an expectation that access to ART was conditional upon treated drug use in a setting of limited drug treatment opportunity; and 'system verticalization', where a lack of integration across HIV, tuberculosis (TB) and drug treatment compromised access to ART. Taken together, we find that systemic factors play a key role in shaping access to ART with the potential adverse effects of reproducing treatment initiation delay and disengagement from treatment. We argue that meso-level systemic factors affecting access to ART for PWID interact with wider macro-level structural forces, including those related to drug treatment policy and the social marginalization of PWID. We note the urgent need for systemic and structural changes to improve access to ART for PWID in this setting, including to simplify bureaucratic procedures, foster integrated HIV, TB and drug treatment services, and advocate for drug treatment policy reform.

Entities:  

Keywords:  HIV/AIDS; Russia; antiretroviral treatment; health systems; people who inject drugs; qualitative study

Mesh:

Substances:

Year:  2012        PMID: 23197431      PMCID: PMC3794461          DOI: 10.1093/heapol/czs107

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  32 in total

1.  Policy resistance to harm reduction for drug users and potential effect of change.

Authors:  Tim Rhodes; Anya Sarang; Peter Vickerman; Matthew Hickman
Journal:  BMJ       Date:  2010-07-13

2.  Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users.

Authors:  Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Robert S Hogg; Julio S G Montaner; Evan Wood
Journal:  Addiction       Date:  2010-03-10       Impact factor: 6.526

Review 3.  Adherence as therapeutic citizenship: impact of the history of access to antiretroviral drugs on adherence to treatment.

Authors:  Vinh-Kim Nguyen; Cyriaque Yapo Ako; Pascal Niamba; Aliou Sylla; Issoufou Tiendrébéogo
Journal:  AIDS       Date:  2007-10       Impact factor: 4.177

4.  Why do health systems matter? Exploring links between health systems and HIV response: a case study from Russia.

Authors:  Elena Tkatchenko-Schmidt; Rifat Atun; Martin Wall; Patrick Tobi; Jürgen Schmidt; Adrian Renton
Journal:  Health Policy Plan       Date:  2010-02-08       Impact factor: 3.344

5.  Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam.

Authors:  Femke A E Lambers; Ineke G Stolte; Charlotte H S B van den Berg; Roel A Coutinho; Maria Prins
Journal:  Int J Drug Policy       Date:  2011-03-09

6.  "You should be grateful to have medicines": continued dependence, altering stigma and the HIV treatment experience in Serbia.

Authors:  Sarah Bernays; Tim Rhodes; Katarina Janković Terźić
Journal:  AIDS Care       Date:  2010

7.  Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: a qualitative study of early rural referrals to the national program.

Authors:  Gerry Hillary Mshana; Joyce Wamoyi; Joanna Busza; Basia Zaba; John Changalucha; Samuel Kaluvya; Mark Urassa
Journal:  AIDS Patient Care STDS       Date:  2006-09       Impact factor: 5.078

8.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

9.  Bridging the gap between antiretroviral access and adherence in Mexico.

Authors:  Lourdes Campero; Cristina Herrera; Tamil Kendall; Marta Caballero
Journal:  Qual Health Res       Date:  2007-05

10.  Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.

Authors:  Laurie Sylla; R Douglas Bruce; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2007-05-10
View more
  24 in total

1.  The HIV epidemic in Eastern Europe and Central Asia.

Authors:  Jack DeHovitz; Anneli Uuskula; Nabila El-Bassel
Journal:  Curr HIV/AIDS Rep       Date:  2014-06       Impact factor: 5.071

2.  If You Build It, Will They Use It? Preferences for Antiretroviral Therapy (ART) Adherence Monitoring Among People Who Inject Drugs (PWID) in Kazakhstan.

Authors:  Alissa Davis; Lyailya Sarsembayeva; Valeriy Gulyaev; Sholpan Primbetova; Assel Terlikbayeva; Gaukhar Mergenova; Robert H Remien
Journal:  AIDS Behav       Date:  2019-12

3.  'PrEP is not ready for our community, and our community is not ready for PrEP': pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response.

Authors:  Andy Guise; Eliot Ross Albers; Steffanie A Strathdee
Journal:  Addiction       Date:  2016-06-08       Impact factor: 6.526

Review 4.  Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups.

Authors:  Onyema Ogbuagu; R Douglas Bruce
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

Review 5.  Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences.

Authors:  Andy Guise; Maureen Seguin; Gitau Mburu; Susie McLean; Pippa Grenfell; Zahed Islam; Sergii Filippovych; Happy Assan; Andrea Low; Peter Vickerman; Tim Rhodes
Journal:  AIDS Care       Date:  2017-03-10

6.  Feasibility and preliminary effects of a screening, brief intervention and referral to treatment model to address gender-based violence among women who use drugs in Kyrgyzstan: Project WINGS (Women Initiating New Goals of Safety).

Authors:  Louisa Gilbert; Tina Jiwatram-Negron; Danil Nikitin; Olga Rychkova; Tara McCrimmon; Irena Ermolaeva; Nadejda Sharonova; Aibek Mukambetov; Timothy Hunt
Journal:  Drug Alcohol Rev       Date:  2016-10-22

7.  Client Acceptability for Integrating Antiretroviral Therapy in Methadone Maintenance Therapy Clinics in Sichuan, China.

Authors:  Chunqing Lin; Li Li; Xiaobin Cao
Journal:  Subst Use Misuse       Date:  2016-09-28       Impact factor: 2.164

8.  Motivators and barriers to HIV testing among street-based female sex workers in St. Petersburg, Russia.

Authors:  Elizabeth J King; Suzanne Maman; Victoria I Dudina; Kathryn E Moracco; J Michael Bowling
Journal:  Glob Public Health       Date:  2015-12-28

9.  Service providers' perceptions of barriers to the implementation of trauma-focused substance use services for women in Cape Town, South Africa.

Authors:  Bronwyn Myers; Tara Carney; Kim Johnson; Felicia A Browne; Wendee M Wechsberg
Journal:  Int J Drug Policy       Date:  2019-12-09

Review 10.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.